Elraglusib
- Generic Name
- Elraglusib
- Drug Type
- Small Molecule
- Chemical Formula
- C22H13FN2O5
- CAS Number
- 1034895-42-5
- Unique Ingredient Identifier
- ND1SOF0DLU
- Background
Elraglusib is under investigation in clinical trial NCT04218071 (Actuate 1901: 9-ING-41 in Myelofibrosis).
9-ING-41 Combined with Retifanlimab, Plus Modified FOLFIRINOX for Patients with Advanced Pancreatic Adenocarcinoma (RiLEY)
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Anwaar Saeed
- Target Recruit Count
- 12
- Registration Number
- NCT06896188
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Anwaar Saeed
- Target Recruit Count
- 32
- Registration Number
- NCT05239182
- Locations
- 🇺🇸
Kansas University Cancer Center, Fairway, Kansas, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
- Conditions
- Soft Tissue SarcomaMyxofibrosarcomaLeiomyosarcomaBone SarcomaUndifferentiated Pleomorphic SarcomaSynovial SarcomaRhabdomyosarcomaHigh Grade SarcomaEwing Sarcoma of BoneAngiosarcoma
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- Brown University
- Registration Number
- NCT05116800
- Locations
- 🇺🇸
Lifespan Cancer Insitute, Providence, Rhode Island, United States
🇺🇸Hasbro Children's Hospital, Providence, Rhode Island, United States
FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer
- Conditions
- Pancreatic Adenocarcinoma MetastaticPancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Colin D. Weekes, M.D., PhD
- Target Recruit Count
- 70
- Registration Number
- NCT05077800
- Locations
- 🇺🇸
Univesity of Colorado, Aurora, Colorado, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸University of Washington, Seattle, Washington, United States
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
- Conditions
- Recurrent Salivary Gland CancerAdenoid Cystic CarcinomaSalivary Gland CancerMetastatic Cancer
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Glenn J. Hanna
- Target Recruit Count
- 35
- Registration Number
- NCT05010629
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
- Conditions
- LiposarcomaSynovial SarcomaBone SarcomaSarcomaSoft Tissue SarcomaMetastatic SarcomaUndifferentiated Pleomorphic SarcomaMyxofibrosarcomaLeiomyosarcomaAngiosarcoma
- Interventions
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Brown University
- Registration Number
- NCT04906876
- Locations
- 🇺🇸
Lifespan Cancer Insitute, Providence, Rhode Island, United States
🇺🇸Hasbro Children's Hospital, Providence, Rhode Island, United States
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
- Conditions
- Salivary Gland CarcinomaAdenoid Cystic CarcinomaSalivary Gland CancerSalivary Gland Neoplasms
- Interventions
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2022-02-22
- Lead Sponsor
- Actuate Therapeutics Inc.
- Registration Number
- NCT04832438
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9-ING-41 in Pediatric Patients with Refractory Malignancies.
- Conditions
- Cancer PediatricPediatric CancerPediatric Brain TumorRefractory CancerRefractory TumorPediatric MeningiomaNeuroblastomaNeuroblastoma RecurrentRefractory NeoplasmPediatric Lymphoma
- Interventions
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Actuate Therapeutics Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT04239092
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Actuate 1901: 9-ING-41 in Myelofibrosis
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Actuate Therapeutics Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04218071
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸Georgia Cancer Center, Augusta, Georgia, United States
9-ING-41 in Patients with Advanced Cancers
- Conditions
- CancerPancreatic CancerPancreatic AdenocarcinomaNeoplasm, BreastNeoplasms PancreaticMalignanciesMalignancies MultipleBone CancerPancreatic NeoplasmsNeoplasm Metastasis
- Interventions
- Drug: Nab paclitaxel.Drug: Doxorubicin.Drug: Carboplatin.Drug: Paclitaxel.
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Actuate Therapeutics Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT03678883
- Locations
- 🇪🇸
Institut Catala d'Oncologia, Barcelona, Spain
🇪🇸Hospital Clinico U San Carlos (HSC), Madrid, Spain
🇪🇸START Madrid-HM CIOCC Hospital Universitario, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.